F4

Benjamin Capital Partners Secures Seed Round To Ignite Future Growth

Retrieved on: 
Thursday, March 28, 2024
Growth, Face, CNET, General partnership, Knowledge, Social media, Sale, Acquisition, IPO, F4, AT&T, Maus, Ecosystem, Starbucks, AOL, Marketing, Interactivity, Video game

NEW YORK and OULU, Finland, March 28, 2024 /PRNewswire/ -- Benjamin Capital Partners announced today the closing of a seed round, raising a total of $5.5 mil. from Play Ventures & F4 Fund. Other prominent investors in the round include inventor, investor, and serial entrepreneur Anton Gauffin; tech CEO and 20-year payment veteran Shane Happach; and Ilkka Teppo, founder of Reworks. The raise will serve to aggressively fuel growth for the Benjamin cash rewards app, which has generated robust consumer demand and revenue growth since its launch in October 2023. Since coming out of beta in October, the Benjamin app already has over 300,000 installs and 195,000 monthly active users (MAUs). Many users are already earning over $100 per month; some are over $1,000 per month in earnings. Moreover, more than 50% of installs are staying as MAUs. Revenue growth has also been very strong, growing north of 40% month over month since October.

Key Points: 
  • NEW YORK and OULU, Finland, March 28, 2024 /PRNewswire/ -- Benjamin Capital Partners announced today the closing of a seed round, raising a total of $5.5 mil.
  • The raise will serve to aggressively fuel growth for the Benjamin cash rewards app, which has generated robust consumer demand and revenue growth since its launch in October 2023.
  • Since coming out of beta in October, the Benjamin app already has over 300,000 installs and 195,000 monthly active users (MAUs).
  • "Play Ventures is very excited to lead the seed round of Benjamin as they continue to build category-defining consumer reward products.

Singular Genomics Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4® Sequencing Platform

Retrieved on: 
Monday, February 5, 2024
SAN, G4S, RNA, Genome Biology, OMIC, Proteomics, Tissue, NGS, F4, Medical imaging

Singular unveiled the G4X™ Spatial Sequencer as a high-throughput in situ spatial sequencing platform capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H&E from formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • Singular unveiled the G4X™ Spatial Sequencer as a high-throughput in situ spatial sequencing platform capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H&E from formalin-fixed, paraffin-embedded (FFPE) tissues.
  • As an upgrade to the G4® Sequencing Platform, the G4X is expected to position Singular to be the only company worldwide to offer capabilities for tissue-based in situ spatial multiomics and NGS on the same instrument.
  • The G4X Spatial Sequencer is on display at the conference, alongside performance data from technology access collaborations with top academic centers.
  • Singular also announced updates to the G4, the industry-leading benchtop sequencing system for speed, flexibility, and power.

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

Retrieved on: 
Wednesday, January 24, 2024
Senior, CMC, CRL, Chemistry, Symantec Endpoint Protection, F4, Lipodystrophy, Risk, Connective tissue, Food, TSX, FDA, HIV, Microbiology

The Company will address the FDA’s request and intends to pursue approval of this newer formulation of tesamorelin.

Key Points: 
  • The Company will address the FDA’s request and intends to pursue approval of this newer formulation of tesamorelin.
  • The questions outlined in the CRL are largely related to chemistry, manufacturing and controls (CMC) concerning the microbiology, assays, impurities and stability for both the lyophilized product and the final reconstituted drug product.
  • In addition, the FDA requested further information to understand the potential impact of the proposed formulation on immunogenicity risk.
  • “While we are disappointed to receive a Complete Response Letter from the FDA for the F8 formulation of tesamorelin containing questions that were not raised during the review process, we plan to address these new comments as swiftly as possible,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies.

Discovering Guizhou along the Belt and Road

Retrieved on: 
Monday, January 29, 2024
Belt and Road Initiative, The, Taste, Beauty, Caucasus Mountains, Letter, Intelligence, F4, LIEN, Child, Transport, Silk Road, Automation, Engineering, Belt

Fast forward to the modern Silk Road, the Belt and Road Initiative, which has facilitated extensive consultation, joint contribution, and shared benefits among countries.

Key Points: 
  • Fast forward to the modern Silk Road, the Belt and Road Initiative, which has facilitated extensive consultation, joint contribution, and shared benefits among countries.
  • The "Ten Years On: Guizhou Story along the Belt and Road" series reports, planned and implemented by Discover Guizhou of Guizhou Daily Press with exclusive support from Kweichow Moutai Co., Ltd., invite you to witness Guizhou stories along the Belt and Road.
  • Currently, 80% of Guizhou Tyre's rubber raw material supply comes from Vietnam, and the Vietnamese factory has provided over 1,000 job opportunities in Tien Giang Province.
  • Every day, thousands of containers carrying Vietnamese-produced Guizhou tires depart from Vietnam, spreading Chinese smart manufacturing across the world.

Discovering Guizhou along the Belt and Road

Retrieved on: 
Thursday, January 25, 2024
Dream, Belt and Road Initiative, The, Taste, University, Mekong Delta, Glass, Caucasus Mountains, Agriculture, Letter, Intelligence, Curriculum, F4, Chishui, Mekong, Road, Travel, LIEN, Multimedia, Wine, Child, Silk, Vocational education, Transport, Silk Road, Automation, Belt, Nightclub

Fast forward to ten years ago, the modern Silk Road facilitated extensive consultation, joint contribution, and shared benefits among countries along the Belt and Road Initiative.

Key Points: 
  • Fast forward to ten years ago, the modern Silk Road facilitated extensive consultation, joint contribution, and shared benefits among countries along the Belt and Road Initiative.
  • The "Ten Years On: Guizhou Story along the Belt and Road" series reports, planned and implemented by Discover Guizhou of Guizhou Daily Press with exclusive support from Kweichow Moutai Co., Ltd., invite you to witness the Guizhou story along the Belt and Road.
  • By integrating into the Belt and Road Initiative, Advance Tyre has not only brought opportunities for Guizhou-manufactured products but also continuously empowered the local community in Vietnam.
  • From Wumeng Mountain to the Caucasus, from the Chishui River to the Mekong River, Guizhou is embracing cooperation and joint development, writing China's stories of sharing prosperity along the Belt and Road.

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

Retrieved on: 
Wednesday, December 20, 2023
Phase, Marketing, GLP1, Food, MRI, Risk, NASH, Euronext Paris, FDA, Breakthrough therapy, DMC, Disease, European, Diabetes, Clinical trial, Glycated hemoglobin, LEGEND, Lipid, Fatty liver disease, NMPA, EIB, Data monitoring committee, Type 2 diabetes, SGLT2, European Investment Bank, BofA Securities, Patient, T2D, Safety, Fibrosis, Data collection, Magnetic resonance imaging, F4, Scan (company), Pharmaceutical industry

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.

Key Points: 
  • The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.
  • Analysis of the baseline characteristics of all patients randomized in the main cohort suggests a patient profile aligned with those of patients randomized in the NATIVE Phase II clinical trial.
  • Lanifibranor continues to show a favorable tolerability profile as confirmed by the third Data Monitoring Committee2 of November 2023.
  • Topline results of the proof-of-concept Phase II clinical trial, LEGEND, evaluating lanifibranor in combination with empagliflozin are expected in the first quarter of 2024.

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

Retrieved on: 
Monday, November 13, 2023
Hepatology, Hyaluronic acid, Safety, Conditional sentence, ACE, ALT, AASLD, Physician, Disease, Risk, Artificial intelligence, Clinical trial, Liver disease, Cirrhosis, KPA, Collagen, Liver, TIMP1, HEPA, Fibrosis, Drug, Doctor of Philosophy, MASH, Patient, ELF, F4, Medical imaging, Pharmaceutical industry, Dietary supplement, F3

EDISON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”; previously referred to as “NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced additional efficacy data for rencofilstat, its lead drug candidate.

Key Points: 
  • Dr. Mayo’s presentation indicated that 17 weeks of rencofilstat treatment was associated with significant reduction in liver stiffness (FibroScan®) in MASH subjects with advanced F3, an outcome suggesting reduction in hepatic fibro-inflammation.
  • Ongoing hepatic fibro-inflammation leads to progressive accumulation of collagen or fibrosis, increasing liver stiffness, and functional deterioration.
  • The predictive power of liver stiffness measurements on the course of disease is further enhanced when taken together with blood-based markers of liver disease.
  • Reduction in liver stiffness by rencofilstat likely indicates reduction in fibroinflammation, and reduction in risk for subsequent clinical outcome.

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
NAFLD, Safety, SAN, Therapy, Cirrhosis, Clinical trial, Patient, DSM-IV codes, Diabetes, Lipid, Lipoprotein, Research, Liver injury, FDA, Extrapyramidal system, EFX, CMO, Biomarker, Fibrosis, AND, Histology, NASH, F4, Biopsy, Pharmaceutical industry, Medical imaging, Cryptocurrency, Åkerö

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.
  • Key secondary endpoints will include changes in biomarkers of liver fibrosis as well as measures of glycemic control and lipids.
  • Akero's cash, cash equivalents and short-term and long-term marketable securities for the period ended September 30, 2023 were $613.0 million.
  • Total operating expenses were $46.6 million for the three-month period ended September 30, 2023, compared to $36.1 million for the comparable period in 2022.

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

Retrieved on: 
Sunday, November 12, 2023
SAN, ALT, F3, Liver, Risk, Disease, Patient, Cirrhosis, Decompensation, FAST, Biomarker, Diabetes, NASH, Inflammation, F2, Fibrosis, Medical device, Boston, F4

SAN FRANCISCO, Nov. 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced additional data from a post-hoc analysis of the ENLIVEN Phase 2b trial evaluating treatment with pegozafermin in a subgroup of patients with F4 NASH. These data were featured in an oral presentation during the AASLD The Liver Meeting®, being held in Boston, Massachusetts.

Key Points: 
  • These data were featured in an oral presentation during the AASLD The Liver Meeting®, being held in Boston, Massachusetts.
  • “Patients with NASH and compensated cirrhosis face a critical imperative to mitigate the risk of decompensation, necessitating therapies that halt or even reverse the progression of fibrosis,” Dr. Hank Mansbach, Chief Medical Officer of 89bio commented.
  • “While the cohort of F4 patients in ENLIVEN was relatively small, we were encouraged by data suggesting that pegozafermin could potentially provide benefits to these patients by addressing both liver pathology and the metabolic irregularities that may contribute to the disease.
  • Treatment with pegozafermin led to clinically meaningful improvements in liver specific biomarkers of stiffness and fibrosis (Pro-C3, FAST, VCTE, FIB-4), inflammation (ALT and AST), and other key non-invasive markers.

89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, November 8, 2023
FDA, Sale, Hynes Convention Center, Research and development, Ballroom, Food, BTD, Liver, Fibrosis, R, F4, NASH, Safety, Patient, Food and Drug Administration, Administration, SAN, Pharmaceutical industry, Cryptocurrency, G&A

SAN FRANCISCO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • SAN FRANCISCO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the third quarter ended September 30, 2023.
  • “We are making excellent progress in developing pegozafermin as a potential leading treatment for liver and cardiometabolic diseases,” stated Rohan Palekar, CEO of 89bio.
  • Additionally, we are continuing to enroll patients in ENTRUST, the Phase 3 trial of pegozafermin in patients with SHTG.
  • As of September 30, 2023, 89bio had cash, cash equivalents and short-term available-for-sale securities totaling $448.3 million.